Posted by Michael Wonder on 15 Oct 2024
Lantern Pharma’s investigational drug candidate, LP-184, receives fast track designation in glioblastoma from the FDA
15 October 2024 - A Phase 1b/2a clinical trial for recurrent glioblastoma is targeted to start in late 2024/early 2025.
Lantern Pharma today announced that the FDA has granted fast track designation for investigational drug candidate, LP-184, for treatment of glioblastoma.
